Jeff Rohr
Reviews 1

I recently had the opportunity to explore the website, and it offered a solid look into the company's products and values. The website's layout and navigation were intuitive, making it easy to find information about their offerings. However, I felt that there could have been more interactive features to engage visitors and provide a more dynamic experience. Additionally, I was hoping to see more in-depth resources and educational materials about the industry and the company's approach. Overall, while the website effectively showcased the company's products, I believe that expanding the depth of content and interactivity could enhance the overall user experience.

Addy Ruiz
Reviews 1

I recently visited Intermune's website and I must say, it was an average experience. The layout of the website was a bit confusing and it took me a while to find the information I was looking for. The website could definitely use some improvements in terms of user-friendliness. However, the content on the website was informative and helpful, which is why I gave it an average rating.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="intermune" data-lang="en"></div>
More widgets

About Intermune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Address
3280 bayshore boulevard
Categories
Biotechnology